Clinical Research Directory

Inclusion Criteria: * Subjects aged at least 18; * Subjects with at least one typical atrial flutter attack recorded by ECG or holter in the 180 days prior to enrollment, and the ECG of other hospitals could be accepted; * Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program. Exclusion Criteria: * Any prior cavo-tricuspid isthmus ablation; * Unstable angina; * Atrial flutter secondary to electrolyte disorder, thyroid disease or other reversible causes; * Myocardial infarction or coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within the prior three months; * At baseline, New York College of Cardiology (NYHA) heart function grades III and IV; * Implantable devices such as ICDs, CRTS and pacemakers in the body; * Atrial or ventricular tumors, blood clots, thrombus, or known clotting disorders were recorded within the prior 90 days; * Severe structural heart disease, including tricuspid stenosis, tricuspid malformation, or other congenital heart disease that prevents ablation surgery; * Previously received tricuspid metal valve replacement; * Thromboembolic events (including transient ischemic attacks) within the past 6 months; * Mural thrombosis, tumor, or other abnormality that interferes with vascular puncture or catheter operation; * Severe lung disease, pulmonary hypertension or any lung disease involving abnormal blood gas or severe breathing difficulties; * Anticoagulation contraindications and a history of blood clotting or abnormal bleeding; * Acute systemic infection; * Serum creatinine greater than twice the upper limit of normal, or any history of renal dialysis; * Women who are pregnant or breastfeeding or who cannot use contraception during the study period; * Enrollment in another clinical trial evaluating other devices or drugs during the same period; * Life expectancy less than 12 months (e.g. advanced malignancy); * Abnormalities or diseases considered by the investigator to be excluded from inclusion in this study.